Status:
COMPLETED
Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
Rhinoconjunctivitis
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
Efficacy and Safety from a high-dosed subcutaneous recombinant preparation
Eligibility Criteria
Inclusion
- Allergic rhinoconjunctivitis attributable to grass pollen
- Positive SPT
- Positive EAST
- Positive provocation test
Exclusion
- serious disease
- other perennial allergies
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
256 Patients enrolled
Trial Details
Trial ID
NCT00671268
Start Date
March 1 2008
End Date
March 1 2013
Last Update
November 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergopharma GmbH & Co. KG
Reinbek, Germany